Poly-Iclc
Ocular Melanoma
Craig L Slingluff, Jrnucleic_acidPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Ocular Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
BELZUPACAP SAROTALOCAN Aura Biosciences | Phase 2 | BB |
Ipilimumab University of Michigan Rogel Cancer Center | Phase 2 | BB |
Nivolumab University of Michigan Rogel Cancer Center | Phase 2 | B |
Aflibercept Centre Hospitalier Universitaire de Nice | Phase 3 | B |
Bel-Sar Aura Biosciences | Phase 3 | B |
View all 25 →
Same molecule, other indications
Poly-Iclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →